• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ESTRO 2026 Congress: GE HealthCare to spotlight AI-enabled solutions to advance precision care across radiation therapy and image-guided interventions

    5/12/26 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care
    Get the next $GEHC alert in real time by email
    • The company will showcase the latest iRT solution, MIM software innovations, and BK Medical technology – advancing speed, connectivity, and personalized medicine across the cancer care pathway.

    At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare (NASDAQ:GEHC) will highlight a portfolio of AI-enabled solutions designed to support clinicians across radiation therapy, theranostics, and image-guided interventions. The company's presence underscores its focus on reducing workflow complexity, improving coordination across departments, and enabling more timely and personalized cancer care.

    According to the World Health Organization, cancer accounts for nearly 10 million deaths globally each yeari, reinforcing the need for technologies that help clinicians deliver timely and precise care while navigating increasingly complex care pathways. GE HealthCare's approach builds on a long-standing commitment to open, vendor-neutral collaboration across the radiation oncology ecosystem, enabling interoperability across multi-vendor environments, which reflects the reality of most cancer centers worldwide. Connecting different imaging, planning, and treatment systems across a single solution can help reduce workflow complexity, improve coordination between multidisciplinary teams, and support more timely, personalized care delivery.

    Reducing time from diagnosis to treatment with iRT

    Especially in radiation oncology, the timeline from diagnosis to treatment is critical for patient outcomes, but fragmented systems and manual processes can delay treatment throughout the patient journey. At ESTRO 2026, GE HealthCare will host live demonstrations of Intelligent Radiation Therapy (iRT), an AI-supported software solution for radiation therapy workflow management designed to reduce the time it takes for patients to progress from diagnosis to treatment.

    Through integration with treatment planning solutions, iRT automates the simulation to treatment plan workflow, helping clinicians create plans in just minutes. Early adopters of iRT have reduced simulation to treatment planning time from seven days to seven minutes through integration with RayStation® by RaySearch Laboratories.ii This is made possible by connecting CT imaging directly to plan generation as data moves automatically to RayStation for segmentation and optimization.

    By seamlessly coordinating workflows in a mixed vendor environment, iRT is designed to improve visibility, reduce manual handoffs, and support timely workflow coordination. Health systems around the world have implemented iRT, including early adopters such as University of Debrecen in Hungary, which is expanding utilization of the solution to their full radiation oncology department and adding the theranostics workflow.

    "The complexity of all systems involved in radiation therapy has historically made it challenging to see the full picture of the patient care pathway as they moved through our department," said Dr. Árpád Kovácsiii, Head of the Radiotherapy Department at Debrecen University. "iRT has fundamentally changed this. We now have more complete and clear visibility as well as increased control over every aspect of our workflow, from initial consultation through treatment delivery."

    Alongside CT-based workflows, GE HealthCare will showcase a dedicated MR-only workflow, iRT MR Directiv, which connects to MR Contour DL, a GE HealthCare developed AI model that automatically contours organs at risk (OAR) on MR images, including head & neck and pelvis. The solution also features MRI Planner, by Spectronic Medical (a GE HealthCare company), a deep learning application designed to generate synthetic CT images using standard MR imaging sequences of the brain, head & neck, and pelvis for MRI-only radiotherapy planning purposes.

    Bringing clarity to complex theranostics workflows

    As a first introduction to European audiences, GE HealthCare will also showcase the newly developed iRT for Theranosticsv. Theranostics treatments often require coordination across multiple specialties, systems, and data sources, making it difficult for clinicians to maintain a clear, end-to-end view of the patient journey.

    The iRT for Theranostics workflow orchestration solution is designed to bring a unified view to this highly complex treatment by integrating with electronic medical records (EMRs) and oncology information systems (OIS). The solution guides care teams step-by-step through the process, helping improve coordination and visibility across departments.

    Extending AI-enabled precision with MIM software

    Additionally, GE HealthCare will highlight advanced oncology solutions from MIM software, designed to help clinicians manage growing data volumes while maintaining efficiency and confidence in decision making.

    • MIM LesionID™ Pro transforms whole-body tumor burden analysis for PSMA PET/CT and SPECT/CT studies into a significantly simplified process. Designed in collaboration with leading theranostics practitioners, MIM LesionID Pro features intuitive, user friendly tools and AI-powered automation aimed at making whole body tumor burden analysis more feasible to incorporate into routine clinical practice—helping reduce physician effort in obtaining patient specific insights to support confident decision making.
    • MIM Contour ProtégéAI+™ redefines auto-contouring in radiation therapy planning through zero-click, AI-driven automation. Leveraging sophisticated machine learning algorithms, it automatically generates precise anatomical contours on CT and MR images at the time of simulation, streamlining workflows while maintaining clinical accuracy. Developed in collaboration with leading institutions, the solution is designed to reduce manual effort and enable clinicians to focus on personalized treatment planning.
    • MIM SurePlan™ MRT advances molecular radiotherapy by transforming radiopharmaceutical therapy dosimetry into a standardized, vendor-neutral workflow. Automation is integrated throughout the process—from reconstruction and segmentation to dose calculation and reporting—helping nuclear medicine departments capture the therapy opportunity without compromising patient care. Designed to support practical, patient-specific dosimetry, MIM SurePlan MRT features deep learning-based auto segmentation, automated registration, and flexible quantitative tools that help streamline workflows and reduce manual effort.

    Empowering smarter procedures with real time guidance

    GE HealthCare will also showcase key surgical visualization and guidance solutions that reflect how this technology is rooted within the company's broader oncology portfolio.

    These solutions include bk3000™ with bkFusion™ powered by MIM software, as well as the bkActiv S™ series, part of the bkPortfolio™ family of Active Imaging systems designed to provide interventional guidance during urology, colorectal and pelvic floor procedures.

    bk3000 with bkFusion is designed to support efficient, on-cart workflows and real-time imaging during MRI-ultrasound fusion prostate biopsy procedures. When used with MIM Symphony Dx™, bk3000 supports collaboration with radiology through prostate and lesion contouring and reorientation. Predictive Fusion® includes the ReSlicer® virtual transducer, which is designed to enable personalized alignment of MRI and ultrasound images to support image registration once the transducer is positioned for the procedure.vi Prostate biopsies performed with bkFusion have been recorded to require as little as seven minutes.vii,viii

    The bkActiv S series is designed to deliver clear visualization of anatomical structures, high-quality imaging and to support real-time decision-making through a modern, intuitive interface. It also includes Prostate Volume Assist (PVA), an AI-enabled urology software feature that automates prostate volume measurement with a one-click process. Available on multiple bk systems, PVA is designed to support workflow efficiency and help clinicians capture an important measurement used in prostate imaging, biopsy and treatment guidance, including during procedures that complement radiology therapy workflows.

    In oncology-related applications, GE HealthCare's Active Imaging portfolio also supports image guidance for procedures such as brachytherapy, fiducial marker placement, and rectal spacer placement, where clear, high-resolution ultrasound visualization is designed to support procedural planning and guidance. Additionally, the portfolio supports imaging during ablative therapies, including cryotherapy, irreversible electroporation and laser ablation.

    "At ESTRO, clinicians come together from across the globe to accomplish a critical shared goal - advancing precision care and improving outcomes for the millions of patients diagnosed with cancer every year," said Dr. Ben Newton, Global Head of Oncology at GE HealthCare. "Across radiation therapy, theranostics, and image guided interventions, our emphasis is on solutions that help clinicians reduce complexity so they can focus on delivering timely and personalized care."

    To learn more about the innovations GE HealthCare will be showcasing at ESTRO 2026, please visit the events page here or stop by the GE HealthCare booth #C10:59 during the congress.

    About GE HealthCare Technologies Inc.

    GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

    GE HealthCare is proud to be among 2026 Fortune World's Most Admired Companies™.

    Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

    i World Health Organization. (2026). Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

    ii Based on two InstaPlan (iRT + RayStation by RaySearch) clinical studies in Europe based on a total of 20 patients. Any results achieved using InstaPlan may vary based on differences in workflows, patient populations or other factors.

    iii Dr. Árpád Kovács is a paid consultant for GE HealthCare. The statements by Dr. Árpád Kovács described here are based on his own opinions and on results that were achieved in his unique setting. Since there is no "typical" hospital and many variables exist, i.e. hospital size, case mix, etc., there can be no guarantee that other customers will achieve the same results.  

    iv The MR Direct Solution is a commercial offering that can include GE HealthCare's Intelligent RT (iRT), MR Contour DL by GE HealthCare, and/or MRI Planner by Spectronic Medical – a GE HealthCare company. MRI Planner is manufactured by Spectronic Medical. Not available in all regions.

    v Technology in development. Not for sale. Not cleared or approved by the U.S. FDA or any global regulator for commercial availability.

    vi ReSlicer® technology (MIM's patent No. 9563948) enables Predictive Fusion®.

    vii Data on file with GE HealthCare, CEUT46378-1 End User Test Report for bkFusion performance testing.

    viii bkFusion, SymphonyDx, and SymphonyDx Lite may be unavailable in your country. Please contact your local representative to confirm availability.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260512934394/en/

    GE HealthCare Media Contact:

    Karin Dalsin

    M +1 612-219-2855

    Karin.Dalsin@gehealthcare.com

    Get the next $GEHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GEHC

    DatePrice TargetRatingAnalyst
    5/21/2026$69.00Sell → Neutral
    UBS
    4/30/2026$65.00Buy → Neutral
    Goldman
    1/15/2026$77.00Neutral → Sell
    UBS
    10/13/2025$86.00Equal Weight
    Barclays
    10/7/2025$83.00Buy → Neutral
    Citigroup
    5/5/2025$73.00Sell → Neutral
    UBS
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    More analyst ratings

    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lobo Kevin bought $641,800 worth of shares (10,000 units at $64.18), increasing direct ownership by 229% to 14,363 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/26/26 6:44:54 PM ET
    $GEHC
    Medical Electronics
    Health Care

    CEO, AIS Rackliffe Philip was granted 16,458 shares, increasing direct ownership by 62% to 43,187 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/19/26 4:05:14 PM ET
    $GEHC
    Medical Electronics
    Health Care

    CEO, Patient Care Solutions Bankes Jeannette covered exercise/tax liability with 5,535 shares, decreasing direct ownership by 13% to 38,357 units (SEC Form 4) (tax withholding)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/19/26 4:04:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

    Issued on behalf of Ventripoint Diagnostics Ltd.A Toronto-based small-cap is converting clinical validation into real-world hospital deployments at the moment AI cardiac imaging procurement is reorganizing globallyNEW YORK, May 19, 2026 /CNW/ -- USA News Group News Commentary — Cardiology has become one of the proving grounds for medical artificial intelligence, and the procurement environment around it has shifted hard in the last twelve months. Hospital networks are no longer content to evaluate clinical accuracy in isolation; they want department-level economic proof before they sign deployment contracts. That shift is reshaping which AI imaging companies can convert pilot data into recur

    5/19/26 8:55:00 AM ET
    $BFLY
    $GEHC
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Computer Software: Programming Data Processing

    ESTRO 2026 Congress: GE HealthCare to spotlight AI-enabled solutions to advance precision care across radiation therapy and image-guided interventions

    The company will showcase the latest iRT solution, MIM software innovations, and BK Medical technology – advancing speed, connectivity, and personalized medicine across the cancer care pathway. At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare (NASDAQ:GEHC) will highlight a portfolio of AI-enabled solutions designed to support clinicians across radiation therapy, theranostics, and image-guided interventions. The company's presence underscores its focus on reducing workflow complexity, improving coordination across departments, and enabling more timely and personalized cancer care. According to the World Health Organization, cancer

    5/12/26 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare next-gen SIGNA MR technology helps advance research discovery and translate innovation into clinical impact

    GE HealthCare to showcase next-gen technologies including helium-free 1.5T MR, advanced 3T scanner and state-of-the-art AI-powered workflow at ISMRM 2026 Advanced MR research tools help simplify collaboration and speed development, empowering researchers to push boundaries As the global magnetic resonance (MR) community convenes for the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE HealthCare (NASDAQ:GEHC) today announced advancements in research tools and MR systems that aim to accelerate discovery, strengthen collaboration across research programs, and turn innovation into meaningful clinical achievements. GE HealthCare continues to inve

    5/11/26 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    SEC Filings

    View All

    SEC Form SD filed by GE HealthCare Technologies Inc.

    SD - GE HealthCare Technologies Inc. (0001932393) (Filer)

    5/29/26 8:25:02 AM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    5/14/26 12:41:59 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    5/14/26 10:19:20 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GE HealthCare upgraded by UBS with a new price target

    UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $69.00

    5/21/26 8:05:07 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare downgraded by Goldman with a new price target

    Goldman downgraded GE HealthCare from Buy to Neutral and set a new price target of $65.00

    4/30/26 7:40:02 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare downgraded by UBS with a new price target

    UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $77.00

    1/15/26 8:32:16 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lobo Kevin bought $641,800 worth of shares (10,000 units at $64.18), increasing direct ownership by 229% to 14,363 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/26/26 6:44:54 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Director Hochman Rodney F bought $100,365 worth of shares (1,618 units at $62.03) (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/13/26 4:19:13 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Director Yang Watkin Phoebe L. was granted 3,586 shares and bought $63,006 worth of shares (1,000 units at $63.01), increasing direct ownership by 50% to 13,702 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/11/26 8:16:07 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Leadership Updates

    Live Leadership Updates

    View All

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

    GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

    4/9/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    10/22/24 4:16:16 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by GE HealthCare Technologies Inc. (Amendment)

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    4/2/24 4:07:29 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Financials

    Live finance-specific insights

    View All

    GE HealthCare reports first quarter 2026 financial results

    Revenue growth of 7.4%, including Organic revenue growth* of 2.9% Total orders up 1.1% organically versus 10.3% growth in the year-ago period; book-to-bill of 1.07 times and backlog of $21.8 billion Profitability in the quarter was impacted by a discrete PDx supplier issue that has since been resolved Net income margin of 7.6% and Adjusted earnings before interest and taxes (EBIT) margin* of 13.5%; diluted earnings per share (EPS) of $0.85 and Adjusted EPS* of $0.99 Cash flow from operating activities of $290 million and Free cash flow* of $112 million For the full-year 2026, Company reaffirms topline growth driven by healthy global end market demand; reduces profit and Free

    4/29/26 6:20:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare to announce first quarter 2026 results on April 29, 2026

    GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutic

    4/6/26 7:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare completes Intelerad acquisition – accelerating shift to cloud-first enterprise solutions to deliver precision care

    Expands GE HealthCare's enterprise imaging footprint by delivering comprehensive, end‑to‑end solutions across ambulatory, teleradiology, and hospital care settings Advances GE HealthCare's D3 strategy by accelerating the development of disease‑focused smart devices and solutions enabled by digital (cloud and software) and artificial intelligence (AI) capabilities Enhances a fully connected, cloud‑first imaging ecosystem with an expanded GE HealthCare portfolio of AI, digital tools, and SaaS offerings designed to improve clinical operations Tuck‑in acquisition expected to strengthen the Imaging portfolio, increase recurring revenue mix, and support sustainable top‑line growth and p

    3/18/26 4:00:00 PM ET
    $GEHC
    Medical Electronics
    Health Care